110 related articles for article (PubMed ID: 24331657)
1. Impact of concomitant chemotherapy on outcomes of radiation therapy for head-and-neck cancer: a population-based study.
Gupta S; Kong W; Booth CM; Mackillop WJ
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):115-21. PubMed ID: 24331657
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of chemoradiation for head and neck cancer in an older patient population.
VanderWalde NA; Meyer AM; Deal AM; Layton JB; Liu H; Carpenter WR; Weissler MC; Hayes DN; Fleming ME; Chera BS
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):30-7. PubMed ID: 24725687
[TBL] [Abstract][Full Text] [Related]
3. Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: results of a population-based cohort study.
Pearcey R; Miao Q; Kong W; Zhang-Salomons J; Mackillop WJ
J Clin Oncol; 2007 Jun; 25(17):2383-8. PubMed ID: 17557951
[TBL] [Abstract][Full Text] [Related]
4. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
Ghadjar P; Simcock M; Zimmermann F; Betz M; Bodis S; Bernier J; Studer G; Aebersold DM;
Radiother Oncol; 2012 Aug; 104(2):213-8. PubMed ID: 22726581
[TBL] [Abstract][Full Text] [Related]
5. Planned post-chemoradiation neck dissection: significance of radiation dose.
Stenson KM; Huo D; Blair E; Cohen EE; Argiris A; Haraf DJ; Vokes EE
Laryngoscope; 2006 Jan; 116(1):33-6. PubMed ID: 16481805
[TBL] [Abstract][Full Text] [Related]
6. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
[TBL] [Abstract][Full Text] [Related]
7. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.
Koutcher L; Sherman E; Fury M; Wolden S; Zhang Z; Mo Q; Stewart L; Schupak K; Gelblum D; Wong R; Kraus D; Shah J; Zelefsky M; Pfister D; Lee N
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):915-22. PubMed ID: 20947269
[TBL] [Abstract][Full Text] [Related]
8. Concomitant chemoradiotherapy versus altered fractionation radiotherapy in the radiotherapeutic management of locoregionally advanced head and neck squamous cell carcinoma: An adjusted indirect comparison meta-analysis.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Head Neck; 2015 May; 37(5):670-6. PubMed ID: 24596112
[TBL] [Abstract][Full Text] [Related]
9. Radiation therapy in the management of head-and-neck cancer of unknown primary origin: how does the addition of concurrent chemotherapy affect the therapeutic ratio?
Chen AM; Farwell DG; Lau DH; Li BQ; Luu Q; Donald PJ
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):346-52. PubMed ID: 20933340
[TBL] [Abstract][Full Text] [Related]
10. A planned neck dissection is not necessary in all patients with N2-3 head-and-neck cancer after sequential chemoradiotherapy.
Soltys SG; Choi CY; Fee WE; Pinto HA; Le QT
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):994-9. PubMed ID: 22137026
[TBL] [Abstract][Full Text] [Related]
11. Tumor volume predicts outcome for advanced head and neck cancer treated with targeted chemoradiotherapy.
Doweck I; Denys D; Robbins KT
Laryngoscope; 2002 Oct; 112(10):1742-9. PubMed ID: 12368607
[TBL] [Abstract][Full Text] [Related]
12. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma.
Nuyts S; Dirix P; Clement PM; Poorten VV; Delaere P; Schoenaers J; Hermans R; Van den Bogaert W
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1088-95. PubMed ID: 18707823
[TBL] [Abstract][Full Text] [Related]
13. Definitive altered fractionation radiotherapy and concomitant weekly cisplatin for locally advanced head and neck cancer.
Boulmay BC; Chera BS; Morris CG; Kirwan J; Riggs CE; Lawson M; Mendenhall WM
Am J Clin Oncol; 2009 Oct; 32(5):488-91. PubMed ID: 19528791
[TBL] [Abstract][Full Text] [Related]
14. Selective neck dissection following adjuvant therapy for advanced head and neck cancer.
Mukhija V; Gupta S; Jacobson AS; Eloy JA; Genden EM
Head Neck; 2009 Feb; 31(2):183-8. PubMed ID: 19031407
[TBL] [Abstract][Full Text] [Related]
15. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.
Harrington K; Berrier A; Robinson M; Remenar E; Housset M; de Mendoza FH; Fayette J; Mehanna H; El-Hariry I; Compton N; Franklin N; Biswas-Baldwin N; Lau M; Legenne P; Kumar R
Eur J Cancer; 2013 May; 49(7):1609-18. PubMed ID: 23265705
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of bone or cartilage invasion of locally advanced head and neck cancers.
Do L; Syed N; Puthawala A; Azawi S; Williams R; Vora N
Am J Clin Oncol; 2010 Dec; 33(6):591-4. PubMed ID: 20065851
[TBL] [Abstract][Full Text] [Related]
17. Reirradiation for head-and-neck cancer: delicate balance between effectiveness and toxicity.
Hoebers F; Heemsbergen W; Moor S; Lopez M; Klop M; Tesselaar M; Rasch C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e111-8. PubMed ID: 21362581
[TBL] [Abstract][Full Text] [Related]
18. Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer.
Nguyen NP; Vos P; Lee H; Borok TL; Karlsson U; Martinez T; Welsh J; Cohen D; Hamilton R; Nguyen N; Nguyen LM; Vinh-Hung V
Oncology; 2008; 75(3-4):186-91. PubMed ID: 18841033
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcomes of T4 locally advanced head and neck cancers with soft tissue invasion or bone and cartilage invasion.
Do L; Puthawala A; Syed N; Azawi S; Williams R; Vora N
Am J Clin Oncol; 2009 Oct; 32(5):477-82. PubMed ID: 19506456
[TBL] [Abstract][Full Text] [Related]
20. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer.
Kovács AF; Mose S; Böttcher HD; Bitter K
Strahlenther Onkol; 2005 Jan; 181(1):26-34. PubMed ID: 15660190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
